Nucleoside analogues containing phosphonate or phosphonamide groups
Novel compounds having structure ( 1 ) wherein Z, is N or CH to form a purine, Y, R 1 , R 2′ and R 2 are defined in the specification, are provided for use in the treatment of tumors and the prophylaxis or treatment of viral infections.
1. A compound having structure (4)
wherein each R a independently is C 1 -C 4 alkyl, or benzyl, each R b independently is C 1 -C 4 alkyl, R 10 is C 1 -C 8 alkyl, or C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl, wherein C 1 -C 8 alkyl is optionally substituted by one C 1 -C 4 alkoxy group or pharmaceutically acceptable salt or enriched optical isomer thereof.
2. A compound having structure (5)
wherein each R b independently is C 1 -C 4 alkyl, or benzyl, R 10 is C 1 -C 4 alkyl; or a pharmaceutically acceptable salt or enriched optical isomer thereof.
3. A compound having structure (7):
wherein
each R c independently is C 1 -C 4 alkyl that is substituted by one C 1 -C 4 alkyl-O—C(O)—O-group; R 10 is C 1 -C 4 alkyl; or a pharmaceutically acceptable salt or an enriched optical isomer thereof.
4. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt, or enriched optical isomer thereof.
5. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 and a carrier.
6. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 2 and a carrier.
7. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 3 and a carrier.
8. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 4 and a carrier.
9. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 3 and a second therapeutic agent selected from an anti-viral agent or an anti-tumor/cancer agent.
10. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 4 and a second therapeutic agent selected from an anti-viral agent or an anti-tumor/cancer agent.